Effectiveness and tolerability of fenfluramine in pediatric and adult patients with developmental and epileptic encephalopathies: A multicenter, retrospective, real‐world clinical‐practice study
Epilepsia · 2026
DOI: 10.1002/epi.70342 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, 2026. Verfasst von Vicente Villanueva und 29 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario y Politécnico La Fe, Member of ERN Epicare, Valencia, Spain. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Myoclonic, Fenfluramine, Lennox Gastaut Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sociedad Española de Epilepsia.
Abstract (Originalsprache)
Objective
Developmental and epileptic encephalopathies (DEEs) are characterized by drug‐resistant seizures and developmental slowing/regression. We examined the efficacy and tolerability of fenfluramine (FFA) in pediatric and adult patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and other DEEs.
Methods
In this multicenter, retrospective, real‐world study, FFA treatment was initiated ≥12 months before database closure. Data from patients' charts at 3, 6 and 12 months were recorded in the Spanish Epilepsy Society's DEEs registry. Effectiveness endpoints included seizure reductions of 100%, ≥75%, and ≥50% (responder), median percent seizure reduction, and seizure worsening. Safety endpoints included adverse event (AE) rates.
Results
The study included 166 patients (LGS, n = 84; DS, n = 42; other DEE, n = 40; mean age 16.6 ± 12.1 years [111 pediatric, median 10.1 years; 55 adult, median 26.5 years]). Patients had a median of 3 prior failed anti‐seizure medications (ASMs). At 12 months, the median FFA dose was 0.49 mg/kg/day, with 77.1% treatment retention. There was a 68.8% median reduction in seizure frequency between baseline and 12 months ( p < .001), with significant reductions across all diagnostic groups (LGS, p < .001; DS, p < .001; other DEE, p = .004). The 12‐month ≥50% responder rate was 61%, with no statistically significant differences according to age. At 12 months, there were significant reductions in the mean number of concomitant ASMs ( p = .004) and the proportion of patients requiring rescue medication ( p < .001). Meaningful improvements in Clinical Global Impression scores for cognition (59.3% of patients), behavior (40.9%), sleep (24.3%), and caregiver (44.8%) domains were observed. At 12 months, AEs were reported in 68.1% of patients (mostly mild‐to‐moderate) and AEs leading to discontinuation in 12%, with no significant differences according to age. Significance FFA was effective, with predictable tolerability, in patients with different DEEs and seizure types, supporting its use as an effective treatment option in pediatric and adult patients with DEEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario y Politécnico La Fe, Member of ERN Epicare, Valencia, Spain.
- Hospital Universitario Niño Jesús, Madrid, Spain.
- Hospital Universitario Lucus Augusti, Lugo, Spain.
- Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain.
- Hospital Universitario Clinico San Carlos, Madrid, Spain.
- Hospital Universitario de Canarias, Santa Cruz de tenerife, Spain.
ORCID-Profile: Vicente Villanueva, Elena González-Alguacil, Victor Soto-Insuga, Alejandro Fernández-Cabrera, Laura Olivié, Juan Rodriguez-Uranga, José Carlos Estévez, Angel Aledo-Serrano, Jesús González de la Aleja, Maria Dolores Castro-Vilanova
Förderung
- Sociedad Española de Epilepsia
Zitieren
APA
Villanueva, V., González-Alguacil, E., Smeyers, P., Hernández, S., Soto-Insuga, V., Fernández-Cabrera, A., Olivié, L., de Santos, T., Parejo, B., Iacampo, L., Ortuño, B., Aparicio, J., Fuentes, M., Rodriguez-Uranga, J., Martínez-Agredano, P., Estévez, J. C., Aledo-Serrano, A., Martin-Alvarez, R., Conejo, D., …, & Serratosa, J. M. (2026). Effectiveness and tolerability of fenfluramine in pediatric and adult patients with developmental and epileptic encephalopathies: A multicenter, retrospective, real‐world clinical‐practice study. Epilepsia. https://doi.org/10.1002/epi.70342
Vancouver
Villanueva V, González-Alguacil E, Smeyers P, Hernández S, Soto-Insuga V, Fernández-Cabrera A, et al. Effectiveness and tolerability of fenfluramine in pediatric and adult patients with developmental and epileptic encephalopathies: A multicenter, retrospective, real‐world clinical‐practice study. Epilepsia. 2026. doi:10.1002/epi.70342
BibTeX
@article{Villanueva2026,
author = {Villanueva, Vicente and González-Alguacil, Elena and Smeyers, Patricia and Hernández, Sara and Soto-Insuga, Victor and Fernández-Cabrera, Alejandro and Olivié, Laura and de Santos, Teresa and Parejo, Beatriz and Iacampo, Lucas and Ortuño, Belén and Aparicio, Javier and Fuentes, Montserrat and Rodriguez-Uranga, Juan and Martínez-Agredano, Paula and Estévez, José Carlos and Aledo-Serrano, Angel and Martin-Alvarez, Rocio and Conejo, David and Baena, Belen and Mercedes-Álvarez, Blanca and López, Yolanda and Sierra-Marcos, Alba and Trincado-Lamuño, Rocio and Ennazeh, Mouna and de la Aleja, Jesús González and Renau, Julia and Castro-Vilanova, Maria Dolores and Romero-Aguilera, Fátima and Serratosa, José M},
title = {Effectiveness and tolerability of fenfluramine in pediatric and adult patients with developmental and epileptic encephalopathies: A multicenter, retrospective, real‐world clinical‐practice study},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70342}
}
EUVIMED